Mangoceuticals, Inc.
MGRX
$2.49
-$0.08-3.11%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 615.90K | 755.10K | 866.90K | 844.90K | 731.50K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 615.90K | 755.10K | 866.90K | 844.90K | 731.50K |
| Cost of Revenue | 235.90K | 312.60K | 362.50K | 323.20K | 300.00K |
| Gross Profit | 380.00K | 442.50K | 504.40K | 521.70K | 431.50K |
| SG&A Expenses | 7.35M | 8.00M | 8.10M | 8.35M | 8.68M |
| Depreciation & Amortization | 721.50K | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -541.70K |
| Total Operating Expenses | 8.72M | 8.72M | 8.87M | 8.92M | 8.65M |
| Operating Income | -8.11M | -7.96M | -8.01M | -8.08M | -7.92M |
| Income Before Tax | -8.71M | -9.33M | -9.13M | -9.02M | -9.21M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.71 | -9.33 | -9.13 | -9.02 | -9.21 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 1.00K | 800.00 | 300.00 | 0.00 | -- |
| Net Income | -8.71M | -9.33M | -9.13M | -9.02M | -9.21M |
| EBIT | -8.11M | -7.96M | -8.01M | -8.08M | -7.92M |
| EBITDA | -7.37M | -7.95M | -7.98M | -8.05M | -7.89M |
| EPS Basic | -5.00 | -5.88 | -6.58 | -7.38 | -9.24 |
| Normalized Basic EPS | -2.92 | -3.67 | -4.11 | -4.61 | -5.77 |
| EPS Diluted | -5.00 | -5.88 | -6.58 | -7.38 | -9.24 |
| Normalized Diluted EPS | -2.92 | -3.67 | -4.11 | -4.61 | -5.77 |
| Average Basic Shares Outstanding | 7.90M | 6.59M | 5.64M | 4.95M | 4.18M |
| Average Diluted Shares Outstanding | 7.90M | 6.59M | 5.64M | 4.95M | 4.18M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |